AHRQ
Migraine in pregnancy: Examining the safety of triptans
Researchers analyzed data from more than 3,800 pregnant patients with migraines over two decades and found no major differences in outcomes such as preterm birth, cesarean delivery, or birth defects in those who used triptans vs. those who did not, according to this AHRQ-funded target trial emulation study published in in Mayo Clinic Proceedings. Importantly, the triptan group reported no cases of miscarriage, ectopic pregnancy, or hypertensive disorders such as preeclampsia. These results suggest that triptans—especially sumatriptan—may be a safe option for pregnant women who require medication to manage severe migraines.
Source:
(2026, January 4). Agency for Healthcare Research and Quality. Subject: Agency for Healthcare Research and Quality (AHRQ) Weekly Digest Bulletin [email]
Wang Z, et al. (2025, July 28). Mayo Clin Proc. Safety of Triptans in Treating Migraines in Pregnant Women: A Target Trial Emulation. https://pubmed.ncbi.nlm.nih.gov/40719668/